Krystal Biotech (NASDAQ:KRYS) Price Target Cut to $375.00 by Analysts at Royal Bank Of Canada

Krystal Biotech (NASDAQ:KRYS) had its target price cut by Royal Bank Of Canada from $400.00 to $375.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 24.52% from the company’s current price.

A number of other research firms have also recently issued reports on KRYS. Citigroup reiterated a “buy” rating on shares of Krystal Biotech in a research note on Thursday, October 15th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Zacks Research cut Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $374.70.

Krystal Biotech Trading Up 1.8%

Shares of Krystal Biotech stock traded up $5.26 during mid-day trading on Tuesday, reaching $301.16. 41,546 shares of the stock were exchanged, compared to its average volume of 327,187. Krystal Biotech has a fifty-two week low of $192.52 and a fifty-two week high of $382.54. The company has a market cap of $8.91 billion, a price-to-earnings ratio of 37.84 and a beta of 0.50. The firm has a 50-day simple moving average of $336.45 and a 200 day simple moving average of $308.70.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. The firm had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, research analysts predict that Krystal Biotech will post 7.33 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at $3,653,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Krystal Biotech during the 2nd quarter worth $3,865,000. Corient Private Wealth LP raised its stake in Krystal Biotech by 767.4% during the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after buying an additional 27,035 shares during the period. Bank of America Corp DE raised its stake in Krystal Biotech by 36.6% during the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after buying an additional 69,840 shares during the period. Finally, Congress Asset Management Co. lifted its holdings in Krystal Biotech by 34.8% during the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock worth $17,986,000 after acquiring an additional 13,949 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter EPS of $2.05, exceeding consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also topped expectations. The results were supported by continued demand for Vyjuvek. Earnings Beat May Change The Case For Krystal Biotech Stock
• Positive Sentiment: Management authorized a $400 million share-repurchase program over two years. Buybacks could support earnings per share and provide near-term demand for the stock. Krystal Biotech’s $400 Million Buyback
• Positive Sentiment: Analysts and market commentary highlighted Vyjuvek’s commercial strength, revenue growth and the possibility that the earnings beat could improve the investment outlook. Krystal Biotech Beats on Vyjuvek Strength
• Neutral Sentiment: Krystal revised its 2026 non-GAAP operating-expense outlook to $155 million–$165 million, reflecting continued investment in its clinical portfolio. Krystal Outlines $400 Million Share Repurchase
• Negative Sentiment: Third-quarter profit declined from the prior year despite the earnings beat, raising concerns about growth quality and the sustainability of profitability. Krystal’s Q3 Profit Declines
• Negative Sentiment: Timelines for parts of Krystal’s development pipeline slipped into 2027, delaying potential catalysts and contributing to investor disappointment. The buyback also creates an opportunity-cost and funding-risk debate while the company continues investing in clinical programs. Krystal Biotech Stock Stays Above Fair Value After Buyback Plan
• Negative Sentiment: With KRYS trading above some estimates of fair value and below its recent highs, investors appear to be demanding stronger forward growth to justify the valuation. Is Krystal Biotech Undervalued?

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.